The identified link between PDK1 and IL-8 supports that the dual targeting of PDK1 (for instance, with DCA) and IL-8 (for instance, with small-molecule antagonists and humanized monoclonal antibodies) should be further studied in ovarian or other cancers as possible novel therapeutic approaches. The gene discussed is PDK1; the disease is cancer.